anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adverse experiences were reported by 92 of 823 patients with subarachnoid hemorrhage (11.2%) who were given nimodipine. The most frequently reported adverse experience was decreased blood pressure in 4.4% of these patients. Twenty-nine of 479 (6.1%) placebo treated patients also reported adverse experiences. The events reported with a frequency greater than 1% are displayed below by dose.

There were no other adverse experiences reported by the patients who were given 0.35 mg/kg q4h, 30 mg q4h or 120 mg q4h. Adverse experiences with an incidence rate of less than 1% in the 60 mg q4h dose group were: hepatitis; itching; gastrointestinal hemorrhage; thrombocytopenia; anemia; palpitations; vomiting; flushing; diaphoresis; wheezing; phenytoin toxicity; lightheadedness; dizziness; rebound vasospasm; jaundice; hypertension; hematoma.

Adverse experiences with an incidence rate less than 1% in the 90 mg q4h dose group were: itching, gastrointestinal hemorrhage; thrombocytopenia; neurological deterioration; vomiting; diaphoresis; congestive heart failure; hyponatremia; decreasing platelet count; disseminated intravascular coagulation; deep vein thrombosis.

As can be seen from the table, side effects that appear related to nimodipine use based on increased incidence with higher dose or a higher rate compared to placebo control, included decreased blood pressure, edema and headaches which are known pharmacologic actions of calcium channel blockers. It must be noted, however, that SAH is frequently accompanied by alterations in consciousness which lead to an under reporting of adverse experiences. Patients who received nimodipine in clinical trials for other indications reported flushing (2.1%), headache (4.1%) and fluid retention (0.3%), typical responses to calcium channel blockers. As a calcium channel blocker, nimodipine may have the potential to exacerbate heart failure in susceptible patients or to interfere with A-V conduction, but these events were not observed.

No clinically significant effects on hematologic factors, renal or hepatic function or carbohydrate metabolism have been causally associated with oral nimodipine. Isolated cases of non-fasting elevated serum glucose levels (0.8%), elevated LDH levels (0.4%), decreased platelet counts (0.3%), elevated alkaline phosphatase levels (0.2%) and elevated SGPT levels (0.2%) have been reported rarely.

To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Disclosed is a multi-stage pore hydrogel medicament sustained-release system based on natural polyphenol, which relates to the field of drug delivery. The system comprises a hydrogel matrix and a supramolecular filler. The supramolecular filler is a complex of a natural bio-based polymer and metal ions. The natural bio-based polymer is selected from one of natural polyphenol, dopamine and derivatives thereof, polysaccharide biomass and protein biomass. The hydrogel matrix is one of chitosan, carboxymethyl chitosan, sodium alginate, carboxymethyl cellulose, hyaluronic acid, collagen, gelatin and agarose. The metal ions are one kind of cations of Al, Fe, Zn, Mn, Ni, Co and V. The supramolecular filler based on the natural bio-based polymer is formed in situ in a hydrogel, and is used for regulating and controlling pores of the hydrogel and generating interactions with different medicaments, so that the release rate of the medicament is adjusted. The supramolecular filler is low in cost and free of toxic and side effects.
Animal African trypanosomosis (AAT) is an important global disease of livestock that causes economic losses of up to 4.5 billion US dollars per year. Thus, eliminating AAT in endemic countries will improve agricultural productivity and economic growth. To prevent AAT, vector control and the development of prophylactic drugs are crucial. Ascofuranone (AF) is a bioactive fungal compound with proven in vitro trypanocidal potency and in vivo treatment efficacy. However, the complex stereoselective synthesis of AF has prevented its cost-effective industrial production. Recently, a genetically modified strain of Acremonium egyptiacum fungus that produces a high yield of AF was developed. Therefore, we hypothesized that the oral administration of the AF-producing fungus itself may be effective against AAT. Hence, this study aimed to evaluate the prophylactic activity of orally administered dry-heat-sterilized A. egyptiacum against Trypanosoma congolense IL3000 infection using a mouse model. The survival rate was significantly prolonged (p = 0.009), and parasitemia was suppressed in all AF-fungus-treated groups (Group 1-9) compared with that in the untreated control group (Group 10). Hence, the trypanocidal activity of AF was retained after dry-heat-sterilization of the AF-producing fungus and that its oral administration effectively prevented AAT. Since AAT is endemic to rural areas with underdeveloped veterinary infrastructure, dry-heat-sterilized A. egyptiacum would be the most cost-effective potential treatment for AAT.
Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is \>90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
PURPOSE: A pharmaceutical composition for prostate cancer treatment containing hs-1793 which is an analogue of resveratrol or pharmaceutically acceptable salt is provided to effectively treat cancer by inducing specific and selective extinction of Aurora B kinase lack cancer. CONSTITUTION: A pharmaceutical composition for prostate cancer treatment contains pharmaceutically acceptable salt or 4-(6-hydroxy-2-naphthyl)-1,3-benzenediol which is represented by chemical formula 1. The cancer is androgen dependent prostate cancer. The cancer is Aurora B kinase lack cancer. 0.001-1000mg/kg of the active ingredient is included. The active ingredient induces apoptosis by causing multi-core or diploidization of the cancer cell. The pharmaceutical composition for the prostate cancer treatment includes 4-(6-hydroxy-2-naphthyl)-1,3-benzenediol represented by the chemical formula 1 or pharmaceutically acceptable salt and Bcl-2 protein family antagonist as active ingredients. The Bcl-2 protein family antagonist is ABT-263 represented by chemical formula 2. The ABT-263 controls Bcl-XL among the Bcl-2 protein family.
The invention discloses a traditional Chinese medicine preparation for chronic interstitial nephropathy, belonging to the invention field of traditional Chinese medicines. The traditional Chinese medicine preparation for chronic interstitial nephropathy adopts radix pseudostellariae, Astragalus membranaceus, radix ophiopogonis, Schisandra chinensis, Eclipta alba, glossy privet fruit, Rhizoma Atractylodis Macrocephalae, poria cocos, pericarpium citri reticulatae, fructus amomi, Chinese yam, pulp of dogwood fruit, semen cuscutae, fried Eucommia ulmoides, fructus rosae laevigatae, Gorgon fruit, raspberry, monkshood, cinnamon, prepared rehmannia root, safflower, red peony root, curcuma zedoary, Ligusticum wallichii, fringed pink and rhizoma alismatis. According to different characteristics of each traditional Chinese medicine, the traditional Chinese medicines are prepared according to proportion after being washed, sliced, preconditioned and then are prepared into the preparation by a special method. The traditional Chinese medicine preparation for chronic interstitial nephropathy has the effects of tonifying kidney, controlling nocturnal emission, nourishing yin, supplementing blood, tonifying qi, promoting the secretion of saliva or body fluid, invigorating spleen and removing dampness. The traditional Chinese medicine preparation for chronic interstitial nephropathy has unique product composition and preparation method. According to clinical verification, the traditional Chinese medicine preparation for chronic interstitial nephropathy has significant curative effect, short treatment period, low price, no adverse reaction and toxic or side effect, and wide market application prospect.
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions [see Clinical Pharmacology (12)] . 

The interactions of pregabalin extended-release tablets with co-administration of other drugs have not been systematically evaluated. Co-administration of the prokinetic drug erythromycin with pregabalin extended-release tablets did not result in any clinically important changes in the pharmacokinetics of pregabalin extended-release tablets [see Clinical Pharmacology (12)] . 

Additional studies have been performed with LYRICA. No pharmacokinetic interactions were observed between LYRICA and carbamazepine, gabapentin, lamotrigine, oral contraceptive, phenobarbital, phenytoin, topiramate, and valproic acid. A similar lack of pharmacokinetic interactions would be expected to occur with pregabalin extended-release tablets. 

Pharmacodynamics

Although no pharmacokinetic interactions were seen with LYRICA and ethanol, lorazepam, or oxycodone, additive effects on cognitive and gross motor functioning were seen when LYRICA was co-administered with these drugs. No clinically important effects on respiration were seen in studies of LYRICA.
A retrospective study was performed between november 2014 and october 2015 in the Metz Hospital Center. Were included 33 patients presenting with treatment-naive keratoconus. Patients responded to a questionnaire that assessed eye rubbing habits, family history of keratoconus, history of atopy. 2 groups were separated: group 1 constituted by 15 eyes with no eye rubbing, and group 2 constituted by 18 eyes with moderate or severe eye rubbing. The following informations were collected: best visual corrected acuity (BCVA), spherical equivalent value (SEV), corneal opacities or Vogt striae. For each eye were performed an anterior segment OCT (AS-OCT) to determine the OCT stage for keratoconus (Fourrier domain OCT classification, 2013), and a Scheimpflug camera imaging to determine the maximal keratometry (Kmax) and the minimal corneal thickness (MCT).
NEW MATERIAL:The indole derivative of formula I (R1 is lower alkyl or aralkyl; R2 is H or lower alkyl; X is two H atoms or O) and its salt. EXAMPLE:2-[N-Benzyl-N-(3-piperidinopropyl)aminomethyl]indole. USE:Pharmaceuticals (when X is two H atoms) and its preparation intermediate (when X is 0). It has long-acting excellent central muscle relaxing activity. PROCESS:A compound of formula I wherein X is 0 can be prepared by reacting the indole-2-carboxylic acid of formula II or its reactive derivative with the piperidinopropylamine derivative of formula III in the presence of a condensation agent or in an inert solvent in the presence of a base at 0 deg.C- room temperature. The product can be converted to another compound of formula I wherein X is two H atoms, e.g. by reducing with a reducing agent such as lithium aluminum hydride in anhydrous ether.
Bimagrumab is a human monoclonal antibody that prevents activin type II receptors (ActRII) from functioning. This antibody has a higher affinity for muscle activin-2 receptors than natural ligands such as activin and myostatin, which act as negative muscle growth regulators. Blocking the activin receptor with bimagrumab could be a new pharmaceutical approach for managing patients with obesity and type 2 diabetes mellitus (T2DM). Bimagrumab has anabolic effects on skeletal muscle mass by preventing myostatin binding and other negative muscle growth regulators. Preclinical animal models have also shown that ActRII blockade promotes actions beyond skeletal muscle, including effects on brown adipose tissue (BAT) differentiation and activity. In a phase 2 randomized clinical trial, ActRII blockade with bimagrumab led to significant loss of total body fat mass (FM), lean mass (LM) gain, and metabolic improvements over 48 weeks in overweight or obese patients with type 2 diabetes. The trial involved [number of participants], and the results showed [specific findings]. Currently, Bimagrumab is being evaluated for its potential to treat muscle wasting, functional loss in hip fractures and sarcopenia, as well as obesity. However, it is essential to note that Bimagrumab also blocks the effects of other ActRII ligands, which play a role in the neurohormonal axes, pituitary, gonads, and adrenal glands. These observations suggest that bimagrumab might represent a new approach for treating patients with obesity and related metabolic disturbances.
Most patients with GNB1 encephalopathy have developmental delay and/or intellectual disability, brain anomalies and seizures. Recently, two cases with GNB1 encephalopathy caused by haploinsufficiency have been reported that also show a Prader-Willi-like phenotype of childhood hypotonia and severe obesity. Here we present three new cases from our expert centre for genetic obesity in which GNB1 truncating and splice variants, probably leading to haploinsufficiency, were identified. They all have obesity, hyperphagia and intellectual deficit. The clinical cases and their weight courses are presented, together with a review of all 68 published cases with GNB1 encephalopathy. Information on weight was not mentioned in most of these articles, so we contacted authors for additional clinical information on weight status and hyperphagia. Of the 42 patients whose weight status we could determine, obesity was present in 8 patients (19%). Obesity is significantly over-represented in the group with truncating and splicing variants. In this group, we see an obesity prevalence of 75%. Since GNB1 has been linked to several key genes in the hypothalamic leptin-melanocortin pathway, which regulates satiety and energy expenditure, our data support the potential association between GNB1 haploinsufficiency and genetic obesity. We also suggest GNB1 is a candidate gene for the known obesity phenotype of the 1p36 microdeletion syndrome given this chromosomal region includes the GNB1 gene. Knowledge of an additional obesity phenotype is important for prognosis, early interventions against obesity and awareness when prescribing weight-inducing medication.
Patients will receive electrical stimulation immediately following carpal tunnel release, per out previous studies. They will receive sham stimulation 1 week prior to surgery to ensure blinding.
Multiple chamber BFR (B-Strong, Park City, UT) training devices will be used for exercise and testing sessions (see attachment). Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) in accordance with manufacturer specifications. The cuffs will maintain pressure during training and rest periods. The LOP will be decreased to 0% immediately after the set is completed.
<P>PROBLEM TO BE SOLVED: To provide a method for preparing fine apatite carbonate, specifically a method for preparing an apatite carbonate fine particle with a controlled particle size.  <P>SOLUTION: In the method for preparing the apatite carbonate fine particle with the controlled particle size, the apatite carbonate fine particle is prepared from an aqueous solution containing phosphoric acid and calcium through deposition. The average particle diameter of the obtained apatite is controlled by controlling the amount of carbonic acid contained in the reaction field atmosphere or in the aqueous solution. A biocompatible member is obtained by the method. The method enables easy modification of the average particle diameter of the apatite carbonate, which is excellent in biocompatibility and specifically adsorbs proteins, by changing the amount of a carbonate source in the reaction system. The apatite carbonate with the controlled particle diameter can be suitably used as a bone filler which is quickly assimilated into the bone, a drug carrier, and the like.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
To have identical conditions to the immunoadsorption, sham apheresis will also be conducted with the TheraSorb LIFE 21 apheresis system over a period of 9-12 days: each participant will receive five sham cycles. For the sham apheresis, a TheraSorb LIFE 21 unit with blocked Ig adsorbers and without regeneration of the adsorbers during the treatment will be used, ensuring that the patient and the investigator are blinded. The study nurses applying the treatment (a specific person only in charge of the patient during the treatment) cannot be blinded.
The invention discloses a fluorine-containing water-soluble platinum complex and its preparation method and use. The fluorine-containing water-soluble platinum complex is shown in the formula (I). The fluorine-containing water-soluble platinum complex has excellent tumor-selective drug accumulation effects and prevents rejection-caused tumor resistance to drugs by targeting delivery to tumor cells. Compared with clinical drugs, the complex has high water solubility and is suitable for clinical preparation. Compared with a clinical drug oxaliplatin, the complex has superiority in cytotoxicity. The fluorine-containing water-soluble platinum complex solves the problem the existing platinum drug has poor water solubility, poor stability and clinical use inconvenience, improves drug targeting effects on tumor cells, and solves the problem that the existing clinical drugs has deficiency in tumor treatment effects, resistance to drugs and toxic or side effect.
A device for sustained drug delivery to the rumen is presented.  The device has a hydrolysable, biodegradable, polymeric core(contg. dissolved or suspended medicament) inside a rumencompativle tube having at least one open end.  The annulus between the core and tube is filled with a relatively thick layer of elastic sealant which acts as adhesive.  This sealant is impermeable to water; unaffected by rumen conditions, and compatible with tube, core and rumen.  The sealant prevents contact between rumen fluid and the walls of the core, so that erosion take place only at the open ends, providing a more consistent release of drug.
Participants will receive two tablets of the test formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
Subjects will receive 24 activated laser acupuncture treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points.
The invention belongs to the technical field of artificial intelligence, and provides a psychological domain data generation method, a psychological domain data model training device and a psychological domain data storage medium. The method aims at solving the problem that an effective method for generating high-quality dialogue data in the psychological field and training a large language model in the vertical field is lacking at present. And inputting a strategy labeling corpus and an open source data set, constructing a Markov chain generation strategy, de-duplicating and initializing a topic and strategy group list for generating multiple rounds of conversations. The most similar dialogue cases are found through strategy matching and provided for the expert language model to guide replies. Templates are defined and populated with cases, questions, and policies, and multiple rounds of conversations are generated and saved as a mental domain dataset. Training a large language model to adapt to multi-round dialogue tasks in the psychological field, and improving the expertise and pertinence by adopting a special identifier, a causal language model and a weighted average loss function.
This research involved an evaluation of the Nutrition and Body Mass Index Clinical Link Pathway (NBMI CLiP) implemented in practice across Severe Mental Illness and/or learning disabilities ward in Tees, Esk and Wear Valleys NHS Foundation Trust (TEWV), to understand how the NBMI CLiP is used, inpatient staff feedback on the CLiP for supporting service users to manage their weight, and whether using the NBMI CLiP impacted on staffs' own weight management. To account for the uneven distribution of the secondary data, descriptive statistics such as medians and the inter-quartile range were conducted to assess anychanges in recording of Body Mass Index, nutrition screening (SANSI) and intervention planss. Staff survey data investigated barriers and facilitators to using the NBMI CLiP in practice and the impact on their own weight management. Secondary data analysis found most wards improved recording of BMI, SANSI and Intervention Planning. Forensic Learning Disabilities, Adult Learning Disabilities, mixed gender wards and North Yorkshire and York Operational Directorate indicated the greatest improvement. Survey results (n = 55) found three times as many participants (n = 12, 75%) found the NBMI CLiP easy or very easy to use; most fully understood it (n = 13, 81.20%) and were confident or very confident to carry out a SANSI Screen (n = 14, 87.50%) or a recovery focused intervention plan (n = 9, 56.20%). Open-text responses, analysed using content analysis, indicated a need for further training of staff on the NBMI CLiP. It is recommended that to support weight management across these wards, that a nudge or choice architecture approach to weight management is adopted, supported by training delivered by a dietitian.